Head-to-head evidence
Paliperidone palmitate (Invega Sustenna) vs Risperidone (Rykindo)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Paliperidone palmitate (Invega Sustenna)
Marketed by Johnson & Johnson
NCT00101634 · Phase 3 · completed
The study was randomized and double-blind, with 518 participants and a placebo comparison, and used a clinical symptom measure (change in total PANSS score) as its primary endpoint. Because no results are posted, it is not possible to determine whether the primary endpoint was met.
Next expected readout: December 2026 · NCT07493551 (registry estimate)
Risperidone (Rykindo)
Marketed by Luye Pharma Group
NCT02055287 · Phase 1 · completed
A non-randomized, open-label, four-dose pharmacokinetic study of Rykindo in 36 participants. With no randomization, no blinding, no comparator arm, and no results posted to the registry, this is weak evidence.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Paliperidone palmitate (Invega Sustenna)'s landscape · Risperidone (Rykindo)'s landscape